[시장보고서]구강 점막염 시장 규모, 점유율, 동향 분석 보고서 : 치료별, 유통 채널별, 지역별, 부문 예측(2025-2033년)

구강 점막염 시장 규모, 점유율, 동향 분석 보고서 : 치료별, 유통 채널별, 지역별, 부문 예측(2025-2033년)

Oral Mucositis Market Size, Share & Trends Analysis Report By Treatment (Growth Factor, Barrier, Topical Analgesics, Cryotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1869805

리서치사 : Grand View Research

발행일 : 2025년 10월

페이지 정보 : 영문 125 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,876,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,368,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,351,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

구강 점막염 시장 요약

세계의 구강 점막염 시장 규모는 2024년에 15억 달러로 평가되었고, 2033년까지 28억 5,000만 달러에 이를 것으로 예측됩니다.

2025년부터 2033년까지 연평균 복합 성장률(CAGR) 7.35%를 나타낼 전망입니다. 구강 점막염(OM)의 임상 부담 증가는 구강 점막염 시장의 성장을 견인하는 주요 요인 중 하나입니다.

구강 점막염은 화학요법 및 방사선요법의 빈도가 높은 합병증이며, 암치료 증가가 더욱 구강 점막염 시장에 호영향을 주고 있습니다. 게다가 지지요법의 선택지에 대한 인식 증가와 암 치료 중 환자의 삶의 질(QOL) 향상의 필요성이 시장 수요를 뒷받침하고 있습니다. 구강 점막염의 예방 및 치료적 개입에 대한 지속적인 R&D도 시장 성장을 가속하고 있습니다.

매일 증가하는 암 증례 수가 구강 점막염 산업의 성장을 견인하고 있습니다. 세계보건기구(WHO)는 2050년까지 신규 암 증례가 3,500만 건을 넘을 것으로 예측하고 있으며, 이는 2022년 추정 2,000만 건에서 77% 증가하는 수치입니다. 이것은 인구의 고령화와 증가를 반영한 수치입니다. 이 증가에 의해 화학요법이나 방사선요법을 받는 환자수가 증가해, 부작용으로서 구강 점막염을 빈번하게 발병하는 결과가 되고 있습니다. 게다가 암치료법의 진보에 의해 생존율이 향상되어 지지요법을 필요로 하는 환자층이 확대되고 있습니다. 효과적인 구강 점막염 치료에 대한 수요가 증가하고 있으며 시장은 계속 성장하고 있습니다.

정기적인 임상 평가 및 관리 지침의 진보는 구강 점막염 치료를 지원합니다. 2024년 6월 다국적 암 지지 요법 학회(MASCC)와 국제 구강 종양 학회(ISOO)는 임상시험에서 구강 점막염 평가에 WHO 구강 독성 규모를 권장하는 업데이트 가이드라인을 발표했습니다. 이 국제 기준은 방사선 치료 및 조혈 줄기 세포 이식(HSCT)과 같은 다양한 평가 환경에서 표준화를 지원합니다. 본 가이드라인은 환자 모니터링 개선, 신규 치료 개발 촉진, 효과적인 구강 점막염 개입의 보급에 기여하고 시장 성장을 견인할 것으로 기대됩니다.

지역별 시장 점유율 분석(2024년 및 2033년)
지역 시장 대시보드
시장 규모와 예측 동향 분석(2021-2033년)
북미
- 국가별(2021-2033년)
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제7장 경쟁 구도

참가자 개요
기업의 시장 포지셔닝 분석
기업 분류
전략 매핑
기업 프로파일
- Amgen Inc.
- EpicentRx, Inc.
- Pfizer Inc.
- Soleva Pharma, LLC.
- Basic Pharma Life Science Pvt Ltd.
- CANbridge Pharmaceuticals Inc.
- Enzychem Lifesciences Corporation
- Galera Therapeutics, Inc.
- Helsinn Healthcare SA.
- Monopar Therapeutics, Inc.
- Swedish Orphan Biovitrum AB
- Innovation Pharmaceuticals Inc.

KTH

영문 목차

영문목차

Oral Mucositis Market Summary

The global oral mucositis market size was estimated at USD 1.50 billion in 2024 and is projected to reach USD 2.85 billion by 2033, growing at a CAGR of 7.35% from 2025 to 2033. The rising clinical burden of Oral Mucositis (OM) is one of the major factors driving the market growth for oral mucositis.

OM is a frequent complication of chemotherapy and radiotherapy, and increasing cancer treatment further impacts the OM market positively. In addition, the growing awareness of supportive care options and the need to improve patients' quality of life during cancer treatment are boosting market demand. Continuous research and development in preventive and therapeutic interventions for oral mucositis is also driving the market's growth.

Increasing cases of cancer day by day are driving growth in the oral mucositis industry. The World Health Organization (WHO) projects over 35 million new cancer cases by 2050, a 77% increase from an estimated 20 million cases in 2022, reflecting both population aging and growth. This increase leads to a larger number of patients undergoing chemotherapy and radiotherapy, which frequently results in oral mucositis as a side effect. Furthermore, improvements in cancer therapies have enhanced survival rates, expanding the population requiring supportive care. Demand for effective oral mucositis treatments is increasing, and the market is growing.

Advancements in regular clinical assessment and management guidelines support oral mucositis treatment. In June 2024, the Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO) released updated guidance recommending the WHO Oral Toxicity Scale for OM assessment in clinical trials. This global standard assists in standardizing assessment within various evaluation environments, such as radiotherapy and hematopoietic stem cell transplantation (HSCT). These guidelines will help ensure better patient monitoring, accelerate the development of new treatments, and promote effective OM interventions more widely, which is expected to drive market growth.

Global Oral Mucositis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oral mucositis market report based on treatment, distribution channel, and region:

Treatment Outlook (Revenue, USD Million, 2021 - 2033)
Growth factor / Epithelial Protective Agents
Barrier/ Coating Gels and Rinses
Topical analgesics
Cryotherapy
Low-level Laser/ Photobiomodulation therapy (LLLT)
Antimicrobials
Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Other
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Treatment
- 1.2.2. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Oral Mucositis Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis

Chapter 4. Oral Mucositis Market: Treatment Business Analysis

4.1. Treatment Market Share, 2024 & 2033
4.2. Treatment Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
4.4. Growth Factor /Epithelial Protective Agents
- 4.4.1. Growth Factor /Epithelial Protective Agents Market, 2021 - 2033 (USD Million)
4.5. Barrier/Coating Gels and Rinses
- 4.5.1. Barrier/Coating Gels and Rinses Market, 2021 - 2033 (USD Million)
4.6. Topical Analgesics
- 4.6.1. Topical Analgesics Market, 2021 - 2033 (USD Million)
4.7. Cryotherapy
- 4.7.1. Cryotherapy Market, 2021 - 2033 (USD Million)
4.8. Low-level Laser/Photobiomodulation Therapy (LLLT)
- 4.8.1. Low-level Laser/Photobiomodulation Therapy Market, 2021 - 2033 (USD Million)
4.9. Antimicrobials
- 4.9.1. Antimicrobials Market, 2021 - 2033 (USD Million)

Chapter 5. Oral Mucositis Market: Distribution Channel Business Analysis

5.1. Distribution Channel Market Share, 2024 & 2033
5.2. Distribution Channel Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
5.4. Hospital Pharmacies
- 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
5.5. Retail Pharmacies
- 5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
5.6. Other
- 5.6.1. Other Market, 2021 - 2033 (USD Million)

Chapter 6. Oral Mucositis Market: Regional Estimates & Trend Analysis

6.1. Regional Market Share Analysis, 2024 & 2033
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
6.4. North America
- 6.4.1. North America Oral Mucositis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 6.4.2. U.S.
  - 6.4.2.1. Key Country Dynamics
  - 6.4.2.2. Type Disease Prevalence
  - 6.4.2.3. Regulatory Framework
  - 6.4.2.4. Reimbursement Framework
  - 6.4.2.5. U.S. Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.3. Canada
  - 6.4.3.1. Key Country Dynamics
  - 6.4.3.2. Type Disease Prevalence
  - 6.4.3.3. Regulatory Framework
  - 6.4.3.4. Reimbursement Framework
  - 6.4.3.5. U.S. Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.4. Mexico
  - 6.4.4.1. Key Country Dynamics
  - 6.4.4.2. Type Disease Prevalence
  - 6.4.4.3. Regulatory Framework
  - 6.4.4.4. Reimbursement Framework
  - 6.4.4.5. Mexico Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Europe
- 6.5.1. Europe Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.2. UK
  - 6.5.2.1. Key Country Dynamics
  - 6.5.2.2. Type Disease Prevalence
  - 6.5.2.3. Regulatory Framework
  - 6.5.2.4. Reimbursement Framework
  - 6.5.2.5. Uk Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.3. Germany
  - 6.5.3.1. Key Country Dynamics
  - 6.5.3.2. Type Disease Prevalence
  - 6.5.3.3. Regulatory Framework
  - 6.5.3.4. Reimbursement Framework
  - 6.5.3.5. Germany Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.4. France
  - 6.5.4.1. Key Country Dynamics
  - 6.5.4.2. Type Disease Prevalence
  - 6.5.4.3. Regulatory Framework
  - 6.5.4.4. Reimbursement Framework
  - 6.5.4.5. France Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.5. Italy
  - 6.5.5.1. Key Country Dynamics
  - 6.5.5.2. Type Disease Prevalence
  - 6.5.5.3. Regulatory Framework
  - 6.5.5.4. Reimbursement Framework
  - 6.5.5.5. Italy Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.6. Spain
  - 6.5.6.1. Key Country Dynamics
  - 6.5.6.2. Type Disease Prevalence
  - 6.5.6.3. Regulatory Framework
  - 6.5.6.4. Reimbursement Framework
  - 6.5.6.5. Spain Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.7. Denmark
  - 6.5.7.1. Key Country Dynamics
  - 6.5.7.2. Type Disease Prevalence
  - 6.5.7.3. Regulatory Framework
  - 6.5.7.4. Reimbursement Framework
  - 6.5.7.5. Denmark Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.8. Sweden
  - 6.5.8.1. Key Country Dynamics
  - 6.5.8.2. Type Disease Prevalence
  - 6.5.8.3. Regulatory Framework
  - 6.5.8.4. Reimbursement Framework
  - 6.5.8.5. Sweden Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.9. Norway
  - 6.5.9.1. Key Country Dynamics
  - 6.5.9.2. Type Disease Prevalence
  - 6.5.9.3. Regulatory Framework
  - 6.5.9.4. Reimbursement Framework
  - 6.5.9.5. Norway Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Asia Pacific
- 6.6.1. Asia Pacific Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.2. Japan
  - 6.6.2.1. Key Country Dynamics
  - 6.6.2.2. Type Disease Prevalence
  - 6.6.2.3. Regulatory Framework
  - 6.6.2.4. Reimbursement Framework
  - 6.6.2.5. Japan Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.3. China
  - 6.6.3.1. Key Country Dynamics
  - 6.6.3.2. Type Disease Prevalence
  - 6.6.3.3. Regulatory Framework
  - 6.6.3.4. Reimbursement Framework
  - 6.6.3.5. China Oral MucositisMarket Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.4. India
  - 6.6.4.1. Key Country Dynamics
  - 6.6.4.2. Type Disease Prevalence
  - 6.6.4.3. Regulatory Framework
  - 6.6.4.4. Reimbursement Framework
  - 6.6.4.5. India Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.5. Australia
  - 6.6.5.1. Key Country Dynamics
  - 6.6.5.2. Type Disease Prevalence
  - 6.6.5.3. Regulatory Framework
  - 6.6.5.4. Reimbursement Framework
  - 6.6.5.5. Australia Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.6. South Korea
  - 6.6.6.1. Key Country Dynamics
  - 6.6.6.2. Type Disease Prevalence
  - 6.6.6.3. Regulatory Framework
  - 6.6.6.4. Reimbursement Framework
  - 6.6.6.5. South Korea Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.7. Thailand
  - 6.6.7.1. Key Country Dynamics
  - 6.6.7.2. Type Disease Prevalence
  - 6.6.7.3. Regulatory Framework
  - 6.6.7.4. Reimbursement Framework
  - 6.6.7.5. Thailand Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Latin America
- 6.7.1. Latin America Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7.2. Brazil
  - 6.7.2.1. Key Country Dynamics
  - 6.7.2.2. Type Disease Prevalence
  - 6.7.2.3. Regulatory Framework
  - 6.7.2.4. Reimbursement Framework
  - 6.7.2.5. Japan Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7.3. Argentina
  - 6.7.3.1. Key Country Dynamics
  - 6.7.3.2. Type Disease Prevalence
  - 6.7.3.3. Regulatory Framework
  - 6.7.3.4. Reimbursement Framework
  - 6.7.3.5. China Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Middle East and Africa
- 6.8.1. Middle East and Africa Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.8.2. South Africa
  - 6.8.2.1. Key Country Dynamics
  - 6.8.2.2. Type Disease Prevalence
  - 6.8.2.3. Regulatory Framework
  - 6.8.2.4. Reimbursement Framework
  - 6.8.2.5. South Africa Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.8.3. Saudi Arabia
  - 6.8.3.1. Key Country Dynamics
  - 6.8.3.2. Type Disease Prevalence
  - 6.8.3.3. Regulatory Framework
  - 6.8.3.4. Reimbursement Framework
  - 6.8.3.5. Saudi Arabia Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.8.4. UAE
  - 6.8.4.1. Key Country Dynamics
  - 6.8.4.2. Type Disease Prevalence
  - 6.8.4.3. Regulatory Framework
  - 6.8.4.4. Reimbursement Framework
  - 6.8.4.5. UAE Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.8.5. Kuwait
  - 6.8.5.1. Key Country Dynamics
  - 6.8.5.2. Type Disease Prevalence
  - 6.8.5.3. Regulatory Framework
  - 6.8.5.4. Reimbursement Framework
  - 6.8.5.5. Kuwait Oral Mucositis Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
- 7.5.1. Amgen Inc.
  - 7.5.1.1. Overview
  - 7.5.1.2. Financial Performance
  - 7.5.1.3. Product Benchmarking
  - 7.5.1.4. Strategic Initiatives
- 7.5.2. EpicentRx, Inc.
  - 7.5.2.1. Overview
  - 7.5.2.2. Financial Performance
  - 7.5.2.3. Product Benchmarking
  - 7.5.2.4. Strategic Initiatives
- 7.5.3. Pfizer Inc.
  - 7.5.3.1. Overview
  - 7.5.3.2. Financial Performance
  - 7.5.3.3. Product Benchmarking
  - 7.5.3.4. Strategic Initiatives
- 7.5.4. Soleva Pharma, LLC.
  - 7.5.4.1. Overview
  - 7.5.4.2. Financial Performance
  - 7.5.4.3. Product Benchmarking
  - 7.5.4.4. Strategic Initiatives
- 7.5.5. Basic Pharma Life Science Pvt Ltd.
  - 7.5.5.1. Overview
  - 7.5.5.2. Financial Performance
  - 7.5.5.3. Product Benchmarking
  - 7.5.5.4. Strategic Initiatives
- 7.5.6. CANbridge Pharmaceuticals Inc.
  - 7.5.6.1. Overview
  - 7.5.6.2. Financial Performance
  - 7.5.6.3. Product Benchmarking
  - 7.5.6.4. Strategic Initiatives
- 7.5.7. Enzychem Lifesciences Corporation
  - 7.5.7.1. Overview
  - 7.5.7.2. Financial Performance
  - 7.5.7.3. Product Benchmarking
  - 7.5.7.4. Strategic Initiatives
- 7.5.8. Galera Therapeutics, Inc.
  - 7.5.8.1. Overview
  - 7.5.8.2. Financial Performance
  - 7.5.8.3. Product Benchmarking
  - 7.5.8.4. Strategic Initiatives
- 7.5.9. Helsinn Healthcare SA.
  - 7.5.9.1. Overview
  - 7.5.9.2. Financial Performance
  - 7.5.9.3. Product Benchmarking
  - 7.5.9.4. Strategic Initiatives
- 7.5.10. Monopar Therapeutics, Inc.
  - 7.5.10.1. Overview
  - 7.5.10.2. Financial Performance
  - 7.5.10.3. Product Benchmarking
  - 7.5.10.4. Strategic Initiatives
- 7.5.11. Swedish Orphan Biovitrum AB
  - 7.5.11.1. Overview
  - 7.5.11.2. Financial Performance
  - 7.5.11.3. Product Benchmarking
  - 7.5.11.4. Strategic Initiatives
- 7.5.12. Innovation Pharmaceuticals Inc.
  - 7.5.12.1. Overview
  - 7.5.12.2. Financial Performance
  - 7.5.12.3. Product Benchmarking
  - 7.5.12.4. Strategic Initiatives

한글목차

구강 점막염 시장 요약

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 구강 점막염 시장의 변수, 동향, 범위

제4장 구강 점막염 시장 : 치료 비즈니스 분석

제5장 구강 점막염 시장 : 유통 채널 비즈니스 분석

제6장 구강 점막염 시장 : 지역별 추정 및 동향 분석